Study for Evaluating Different Methods of Measuring Depression Treatment Response

ClinicalTrials.gov ID: NCT00406952

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00406952. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 4 Randomized, Double-Blind, Placebo Controlled Methodology Study to Evaluate the Time of Onset of AntiDepressant Response in Subjects With Major Depressive Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Purpose of the study is to evaluate use of electronic diaries and voice acoustics for use in future depression clinical trial. Focus is on increased precision of measurement.

Study identification

NCT ID: NCT00406952
Recruitment status: Completed
Study type: Interventional
Phase: Not applicable
Lead sponsor: Pfizer; Industry
Enrollment: 165 participants

Conditions and interventions

Conditions

Depressive Disorder, Major

Interventions

electronic diary Procedure
Sertraline Drug
Placebo Drug
voice acoustics Procedure

Procedure · Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2006 (Type not available)
Primary completion: Not listed
Completion: Aug 2007 (Actual)
Last update posted: Aug 21, 2008

2006 – 2007

United States locations

U.S. sites: 12
U.S. states: 7
U.S. cities: 10

Facility	City	State	ZIP	Site status
Pfizer Investigational Site	Norwich	Connecticut	06360	—
Pfizer Investigational Site	Aventura	Florida	33180	—
Pfizer Investigational Site	Jacksonville	Florida	32216	—
Pfizer Investigational Site	Miami	Florida	33125	—
Pfizer Investigational Site	Miami	Florida	33134	—
Pfizer Investigational Site	Miami	Florida	33143	—
Pfizer Investigational Site	Orlando	Florida	32806	—
Pfizer Investigational Site	Atlanta	Georgia	30328	—
Pfizer Investigational Site	Elmsford	New York	10523	—
Pfizer Investigational Site	Memphis	Tennessee	38119	—
Pfizer Investigational Site	Plano	Texas	75024	—
Pfizer Investigational Site	Midvale	Utah	84047	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00406952, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 21, 2008 · Synced Nov 14, 2026